MA53020A - Protéine de fusion du fviii améliorée et utilisation associée - Google Patents

Protéine de fusion du fviii améliorée et utilisation associée

Info

Publication number
MA53020A
MA53020A MA053020A MA53020A MA53020A MA 53020 A MA53020 A MA 53020A MA 053020 A MA053020 A MA 053020A MA 53020 A MA53020 A MA 53020A MA 53020 A MA53020 A MA 53020A
Authority
MA
Morocco
Prior art keywords
fusion protein
associated use
fviii fusion
enhanced fviii
enhanced
Prior art date
Application number
MA053020A
Other languages
English (en)
Inventor
Xian Chen
Jie Gao
Haitao Hu
Lingli Huang
Xiang Li
Bin Liu
Zijia Ren
Hongsheng Su
Qilei Wang
Shuang Wang
Shuya Wang
Wenwen Wang
Xiaoshan Wang
Yali Wang
Chunfeng Xiao
Lili Zhang
Luyan Zhu
Original Assignee
Zhengzhou Gensciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Gensciences Inc filed Critical Zhengzhou Gensciences Inc
Publication of MA53020A publication Critical patent/MA53020A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA053020A 2018-05-18 2019-05-16 Protéine de fusion du fviii améliorée et utilisation associée MA53020A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810481941 2018-05-18

Publications (1)

Publication Number Publication Date
MA53020A true MA53020A (fr) 2021-05-05

Family

ID=68539524

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053020A MA53020A (fr) 2018-05-18 2019-05-16 Protéine de fusion du fviii améliorée et utilisation associée

Country Status (9)

Country Link
US (1) US20210361775A1 (fr)
EP (1) EP3816181A4 (fr)
JP (2) JP2021530437A (fr)
KR (1) KR102575788B1 (fr)
CN (2) CN113039200B (fr)
BR (1) BR112020023168A2 (fr)
MA (1) MA53020A (fr)
MX (1) MX2020012103A (fr)
WO (1) WO2019219049A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227015A1 (fr) * 2022-05-25 2023-11-30 江苏晟斯生物制药有限公司 Conjugué de protéine de fusion fviii ayant une demi-vie étendue et son utilisation
CN116284411B (zh) * 2023-02-03 2024-02-13 北京基科晟斯医药科技有限公司 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818679A (en) 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
AU8576298A (en) * 1997-07-18 1999-02-10 Chiron Corporation Lentiviral vectors
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2977055A1 (fr) * 2010-02-16 2016-01-27 Novo Nordisk A/S Protéines de fusion de facteur viii
CN102770449B (zh) * 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
CN103917554B (zh) * 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
CN103172745A (zh) * 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
WO2013106787A1 (fr) * 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Facteur viii chimérique et polypeptides et leurs utilisations
US10023628B2 (en) * 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
WO2014026954A1 (fr) * 2012-08-13 2014-02-20 Novo Nordisk A/S Formulations liquides de facteur viii
ES2657291T3 (es) * 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3400002B1 (fr) * 2016-01-07 2022-02-02 CSL Behring Lengnau AG Facteur de von willebrand tronqué muté
US11046749B2 (en) * 2016-06-24 2021-06-29 Mogam Institute For Biomedical Research Chimera protein comprising FVIII and vWF factors, and use thereof
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
WO2019219049A1 (fr) 2019-11-21
EP3816181A1 (fr) 2021-05-05
EP3816181A4 (fr) 2022-04-20
MX2020012103A (es) 2021-01-29
US20210361775A1 (en) 2021-11-25
JP2023093634A (ja) 2023-07-04
KR102575788B1 (ko) 2023-09-08
CN113039200A (zh) 2021-06-25
CN117467019A (zh) 2024-01-30
CN113039200B (zh) 2023-07-25
KR20210005248A (ko) 2021-01-13
JP7492780B2 (ja) 2024-05-30
BR112020023168A2 (pt) 2021-02-09
JP2021530437A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA51291A (fr) Protéines de fusion il-2 fc modifiées
IL281954A (en) Heterodimeric chimeric proteins
IL279510A (en) Progranulin-FC polypeptide fusion proteins and their uses
MA44993A (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
IL279505A (en) Chimeric transmembrane protein and its uses
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3280727T3 (da) Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf
MA40721A (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
SG11202013170RA (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
DK3900808T3 (da) Adskillelsesindretning og adskillelsesfremgangsmåde
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
MA53020A (fr) Protéine de fusion du fviii améliorée et utilisation associée
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
DK3784047T3 (da) Gærproteiner
EP3722305A4 (fr) Protéine de fusion hm-3 et son utilisation
SG11202110400QA (en) Fusion protein and use thereof
EP3882277A4 (fr) Protéine de fusion et son utilisation
IL279057A (en) Antimicrobial fusion proteins containing endolysin and their uses